Novartis gains priority review for SMA gene therapy as investors grapple with sticker shock
An FDA approval for the world’s first $4 million gene therapy could arrive in as soon as five months.
Novartis says that regulators have opened …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
